Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
View Patent ↗Methods are provided for coating crystalline microparticles with an active agent by altering the surface properties of the microparticles in order to facilitate favorable association on the microparticle by the active agent. Types of surface properties that are altered by the disclosed methods include electrostatic properties, hydrophobic properties, and hydrogen bonding properties.
1. A method for coating a crystalline microparticle with an active agent in a suspension, the method comprising the following sequential steps: (i) dissolving the active agent in a solvent; (ii) obtaining a crystalline diketopiperazine microparticle wherein the crystalline diketopiperazine microparticle does not comprise an active agent; (iii) forming a suspension comprising the crystalline diketopiperazine microparticle, the active agent, and the solvent; (iv) increasing pH of the suspension from about pH 3.0 to between about pH 4.4 and about pH 5; (v) adsorbing the active agent onto a surface of the crystalline diketopiperazine microparticle to provide a coating of the active agent on the crystalline diketopiperazine microparticle; and (vi) removing or exchanging the solvent after step (v), wherein the crystalline diketopiperazine microparticle comprises about 9% to about 12% active agent by weight after removing or exchanging the solvent.
2. The method of claim 1 , wherein the active agent is an insulin or an insulin analog.
3. The method of claim 1 , wherein the core of the crystalline diketopiperazine microparticle microparticle comprises polysorbate 80 .
4. The method of claim 3 , wherein the crystalline diketopiperazine microparticle comprises at least 0.7% polysorbate 80 by weight.
5. The method of claim 4 , wherein crystalline diketopiperazine microparticle comprises between 0.7% and 3.5% polysorbate 80 by weight.
6. The method of claim 1 , wherein the active agent coating on the resulting microparticle is predominantly a monolayer.
7. The method of claim 1 , wherein at least a portion of the active agent is electrostatically bound to the crystalline diketopiperazine microparticle.
8. The method of claim 7 , wherein a majority of the active agent coating is bound to the crystalline diketopiperazine microparticle.
9. The method of claim 1 , wherein the active agent comprises at least one of a peptide, polypeptide, or a protein.
10. The method of claim 1 , wherein the active agent comprises at least one of insulin, parathyroid hormone, growth hormone, ghrelin, GLP-1, or antibodies.
11. The method of claim 1 , wherein the active agent comprises at least one of insulin, an insulin analog, growth hormone, parathyroid hormone, ghrelin, granulocyte macrophage colony stimulating factor (GM-CSF), glucagon-like peptide 1 (GLP-1), cyclosporins, clopiogrel and PPACK (D-phenylalanyl-L-prolyl-L-arginine chloromethyl ketone), or antibodies and fragments thereof.
12. The method of claim 11 , wherein the antibodies or fragments thereof is selected from the group consisting of humanized antibodies and chimeric antibodies.
13. The method of claim 1 , wherein the active agent is a neuroactive agent.
14. The method of claim 1 , wherein the active agent is a cytotoxic agent.
15. A method for coating a crystalline microparticle with an active agent in a suspension, the method comprising the following sequential steps: (i) dissolving the active agent in a solvent; (ii) obtaining a crystalline diketopiperazine microparticle wherein the crystalline diketopiperazine microparticle does not comprise an active agent; (iii) forming a suspension comprising the crystalline diketopiperazine microparticle, the active agent, and the solvent; (iv) increasing pH of the suspension from about pH 3.0 to between about pH 4.4 and about pH 5; (v) adsorbing the active agent onto a surface of the crystalline diketopiperazine microparticle to provide a coating of the active agent on the crystalline diketopiperazine microparticle; and (vi) removing or exchanging the solvent after step (v), wherein the crystalline diketopiperazine microparticle comprises about 9% to about 12% active agent by weight after removing or exchanging the solvent, wherein the active agent is a vasoactive agent.